The Karakul depression in Pamirs: The first impact structure in Central Asia

The Karakul depression was picked out as the possible impact structure by the study of space images of Tadjikistan. Its striking similarity with some complex impact craters such as Dellen and Gosses Bluff is evident. Our investigations of the Karakul depression in 1987 and 1989-1991 years allowed to determine it as the impact crater with the central uplift. The target of the crater is presented by slightly metamorphosed sedimentary rocks of Paleozoic, intensively folded and intruded with granites during the Gercynian orogeny. The modern structure of north-eastern Pamirs was formed by Alpinian orogeny; the raise of the area in Neogene was about 4000-7000 m

Spectroscopy of Helium Isotope 6He

The excited states of heavy helium isotope 6He were studied in stopped pion absorption in the reactions 9Be

The Large Enriched Germanium Experiment for Neutrinoless Double Beta Decay (LEGEND)

The observation of neutrinoless double-beta decay (0${\nu}{\beta}{\beta}$) would show that lepton number is violated, reveal that neutrinos are Majorana particles, and provide information on neutrino mass. A discovery-capable experiment covering the inverted ordering region, with effective Majorana neutrino masses of 15 - 50 meV, will require a tonne-scale experiment with excellent energy resolution and extremely low backgrounds, at the level of $\sim$0.1 count /(FWHM$\cdot$t$\cdot$yr) in the region of the signal. The current generation $^{76}$Ge experiments GERDA and the MAJORANA DEMONSTRATOR utilizing high purity Germanium detectors with an intrinsic energy resolution of 0.12%, have achieved the lowest backgrounds by over an order of magnitude in the 0${\nu}{\beta}{\beta}$ signal region of all 0${\nu}{\beta}{\beta}$ experiments. Building on this success, the LEGEND collaboration has been formed to pursue a tonne-scale $^{76}$Ge experiment. The collaboration aims to develop a phased 0${\nu}{\beta}{\beta}$ experimental program with discovery potential at a half-life approaching or at $10^{28}$ years, using existing resources as appropriate to expedite physics results.Comment: Proceedings of the MEDEX'17 meeting (Prague, May 29 - June 2, 2017

LEGEND-1000 Preconceptual Design Report

We propose the construction of LEGEND-1000, the ton-scale Large Enriched Germanium Experiment for Neutrinoless $\beta \beta$ Decay. This international experiment is designed to answer one of the highest priority questions in fundamental physics. It consists of 1000 kg of Ge detectors enriched to more than 90% in the $^{76}$Ge isotope operated in a liquid argon active shield at a deep underground laboratory. By combining the lowest background levels with the best energy resolution in the field, LEGEND-1000 will perform a quasi-background-free search and can make an unambiguous discovery of neutrinoless double-beta decay with just a handful of counts at the decay $Q$ value. The experiment is designed to probe this decay with a 99.7%-CL discovery sensitivity in the $^{76}$Ge half-life of $1.3\times10^{28}$ years, corresponding to an effective Majorana mass upper limit in the range of 9-21 meV, to cover the inverted-ordering neutrino mass scale with 10 yr of live time

Применение нового нутрицевтика для улучшения переносимости адъювантной химиотерапии

Introduction. Treatment of malignant neoplasms often requires adjuvant chemotherapy (ACT). In real-life clinical practice, a high proportion of patients develop serious toxicities of anticancer therapy. Thus, the need to reduce treatment toxicity while maintaining the same dose levels of chemotherapeutic agents is a pressing challenge in oncology. This article presents the results of the study assessing the effects of the complex nutraceutical Oncoxin on ACT tolerability.Materials and methods. The study included 133 patients aged 50 to 70 years with stage IIB — IIIC gastric cancer or stage IIB — IIIA non-small-cell lung cancer; 84 patients received Oncoxin, and 49 were in the control group.Results. The study revealed that after two weeks, patients receiving Oncocoxin had a twice higher chance of significant (obvious) improvement in their quality of life (ESAS questionnaire) compared to the control group: OR 2.07 [95% CI 1.00-4.29]. By the end of the follow-up period (3 weeks), patients receiving Oncoxin had a significantly higher albumin level compared to the control group (38.1 [95% CI 37.1-39.1] g/L and 35.5 [95% CI 33.9-37.0], р =0.03, respectively). Moreover, the use of Oncoxin allowed significant reducing ACT-related liver toxicity.Conclusions. This study conducted within our current clinical practice showed for the first time a high efficacy of Oncoxin in improving the quality of life of patients and reducing ACT toxicity.Введение. Лечение злокачественных новообразований часто требует применения адъювантной химиотерапии (АХТ). В реальной клинической практике доля пациентов, имеющих серьёзные проявления токсичности противоопухолевого лечения, достаточно высока. Таким образом, необходимость снижения токсичности терапии и сохранение интенсивности дозы химиопрепаратов являются актуальной задачей онкологии. Данная статья посвящена результатам исследования влияния многокомпонентного нутрицевтика Онкоксин на переносимость АХТ.Материалы и методы. В исследование было включено 133 больных раком желудка МВ-ШС или немелкоклеточным раком лёгких ПВ-ША в возрасте 50- 70 лет; 84 получали Онкоксин, 49 составили контрольную группу.Результаты. Было установлено, что через две недели шансы больных, получавших Онкоксин, на значимое (безусловное) улучшение качества жизни (вопросник ESAS) были в два раза выше в сравнении с группой контроля: ОШ = 2,07 [95% ДИ 1,00- 4,29]. К окончанию периода наблюдения (3 недели) в группе пациентов, использовавших Онкоксин, уровень альбумина был значительно выше в сравнении с контрольной группой (38,1 [95% ДИ 37,1- 39,1] г /л и 35,5 [95% ДИ 33,9-37,0], р = 0,03, соответственно). Кроме этого, применение Онкоксина позволило существенно снизить печёночную токсичность АХТ.Выводы. Данное исследование, проведённое в рамках существующей клинической практики, впервые показало высокую эффективность Онкоксина в улучшении качества жизни пациентов и снижении токсичности АХТ